Vimarsana
Biggest News Aggregation in the World

Jp 4502 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Jp 4502. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Jp 4502 Today - Breaking & Trending Today

Takeda Pharmaceutical Expected to Post 34% Drop in Third-Quarter Net Profit -- Earnings Preview - Vimarsana News

Takeda Pharmaceutical Expected to Post 34% Drop in Third-Quarter Net Profit -- Earnings Preview

By Kosaku Narioka Takeda Pharmaceutical is scheduled to report its third-quarter results on Thursday. Here is what you need to know: NET PROFIT FORECAST:...

Takeda Says FDA Approves Treatment for Colorectal Cancer - Vimarsana News

Takeda Says FDA Approves Treatment for Colorectal Cancer

Pharmaceutical company Takeda said Wednesday that the U.S. Food and Drug Administration approved Fruzaqla as a treatment for certain patients with colorectal...

Neurocrine Biosciences Shares Fall After Two Studies Fail to Achieve Desired Results - Vimarsana News

Neurocrine Biosciences Shares Fall After Two Studies Fail to Achieve Desired Results

By Paul Ziobro Shares of Neurocrine Biosciences fell in late trading after the biopharmaceutical company said that two studies failed to achieve desired...

Takeda Pharmaceutical Shares Slump After It Books 2Q Loss, Cuts Profit Guidance - Vimarsana News

Takeda Pharmaceutical Shares Slump After It Books 2Q Loss, Cuts Profit Guidance

By Kosaku Narioka Takeda Pharmaceutical shares fell sharply after it reported a second-quarter net loss due to impairments on certain products and cut its...

Takeda Pharmaceutical Expected to Post 14% Increase in Second-Quarter Net Profit -- Earnings Preview - Vimarsana News

Takeda Pharmaceutical Expected to Post 14% Increase in Second-Quarter Net Profit -- Earnings Preview

By Kosaku Narioka Takeda Pharmaceutical is scheduled to report second-quarter results on Thursday. Here is what you need to know: NET PROFIT FORECAST: Takeda...